BioNTech Halts Phase 2 mRNA Colorectal Cancer Trial After Safety Board Orders End, Shares Fall 10%

BioNTech terminated its mid-stage clinical trial of autogene cevumeran, its mRNA-based cancer vaccine for colorectal cancer, after the trial's independent Data Safety Monitoring Board advised ending both patient treatment and the trial itself. The German biotech's U.S.-listed shares fell nearly 10% on the news. Partner Roche is also implicated in the scrapped program, dealing a blow to the broader mRNA cancer vaccine field.

The failure hit sector peers: Moderna and Merck, whose competing mRNA cancer vaccine collaboration has drawn significant investor attention, also traded lower in the wake of the announcement. The contrast was sharp given that Reuters had earlier the same day published a feature on Moderna and Merck's mRNA cancer vaccine work as a breakthrough success story, and ZeroHedge noted that Moderna had recently completed a convertible note offering before the sector selloff. The BioNTech halt represents one of the most significant clinical setbacks yet for personalized mRNA oncology treatments.